Profile data is unavailable for this security.
About the company
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The Company is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).
- Revenue in USD (TTM)4.15m
- Net income in USD-131.56m
- Incorporated2011
- Employees68.00
- LocationSyros Pharmaceuticals Inc35 Cambridge Park DriveCAMBRIDGE 02140United StatesUSA
- Phone+1 (617) 744-1340
- Fax+1 (617) 744-1377
- Websitehttps://syros.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reneo Pharmaceuticals Inc | 0.00 | -56.54m | 50.14m | 8.00 | -- | 0.6522 | -- | -- | -1.68 | -1.68 | 0.00 | 2.30 | 0.00 | -- | -- | 0.00 | -49.87 | -- | -53.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -9.35m | 51.87m | 2.00 | -- | 10.40 | -- | -- | -0.3633 | -0.3633 | 0.00 | 0.1922 | 0.00 | -- | -- | 0.00 | -91.51 | -- | -104.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.89 | -- | -- | -- |
| Syros Pharmaceuticals Inc | 4.15m | -131.56m | 53.08m | 68.00 | -- | -- | -- | 12.80 | -4.30 | -4.30 | 0.1222 | -0.2369 | 0.0288 | -- | -- | 61,000.00 | -91.46 | -54.44 | -112.06 | -64.32 | -- | -- | -3,171.70 | -772.82 | -- | -- | 1.18 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| Serina Therapeutics Inc | 179.00k | -18.67m | 53.38m | 4.00 | -- | -- | -- | 298.20 | -9.72 | -9.72 | 0.0403 | -1.86 | 0.0156 | -- | 6.28 | 44,750.00 | -162.58 | -194.46 | -- | -- | 49.72 | 85.80 | -10,438.55 | -2,347.36 | -- | -1.82 | -- | -- | 317.65 | -36.69 | -41.49 | -- | -- | -- |
| Angion Biomedica Corp | 0.00 | -38.66m | 54.84m | 32.00 | -- | -- | -- | -- | -4.83 | -4.83 | 0.00 | -0.161 | 0.00 | -- | -- | 0.00 | -144.89 | -105.91 | -202.49 | -331.69 | -- | -- | -- | -712.81 | -- | -- | -- | -- | -100.00 | -- | 9.31 | -- | -- | -- |
| Aerovate Therapeutics Inc | 0.00 | -87.94m | 55.14m | 51.00 | -- | 0.5838 | -- | -- | -3.14 | -3.14 | 0.00 | 3.27 | 0.00 | -- | -- | 0.00 | -65.76 | -- | -74.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
| Prenetics Global Ltd | 22.25m | -49.97m | 55.28m | 320.00 | -- | 0.2413 | -- | 2.48 | -4.33 | -5.32 | 1.91 | 18.75 | 0.0832 | 3.89 | 4.53 | 69,535.41 | -19.43 | -- | -23.55 | -- | 45.56 | -- | -233.41 | -- | 2.25 | -5.17 | 0.0086 | -- | 65.17 | -- | 75.91 | -- | -- | -- |
| Actinium Pharmaceuticals Inc | 81.00k | -42.62m | 55.45m | 49.00 | -- | 1.24 | -- | 684.63 | -1.52 | -1.52 | 0.0029 | 1.43 | 0.0009 | -- | -- | 1,653.06 | -45.12 | -46.98 | -50.13 | -52.71 | -- | -- | -52,620.99 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
| Kronos Bio Inc | 8.41m | -102.85m | 55.48m | 58.00 | -- | 0.4503 | -- | 6.60 | -1.75 | -1.75 | 0.1425 | 2.04 | 0.0396 | -- | -- | 135,661.30 | -48.41 | -35.47 | -53.26 | -37.14 | -- | -- | -1,222.83 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
| Hookipa Pharma Inc | 52.16m | -48.60m | 55.69m | 151.00 | -- | 0.6471 | -- | 1.07 | -5.28 | -5.28 | 4.85 | 7.14 | 0.33 | -- | 309.57 | 345,450.30 | -30.74 | -41.63 | -40.15 | -50.26 | -- | -- | -93.16 | -366.65 | -- | -- | 0.00 | -- | 41.27 | 21.41 | -25.67 | -- | 14.11 | -- |
| Celularity Inc | 22.77m | -196.30m | 56.28m | 120.00 | -- | 1.21 | -- | 2.47 | -11.29 | -11.29 | 1.30 | 2.11 | 0.0836 | 2.90 | 2.39 | 189,758.30 | -72.04 | -19.19 | -94.47 | -20.99 | 29.66 | -- | -862.04 | -454.79 | 0.2086 | 1.37 | 0.4893 | -- | 26.68 | -- | -1,483.14 | -- | -- | -- |
| VolitionRX Ltd | 976.52k | -32.42m | 56.57m | 110.00 | -- | -- | -- | 57.93 | -0.4032 | -0.4032 | 0.0121 | -0.263 | 0.0481 | -- | 5.38 | 8,877.45 | -161.39 | -111.92 | -- | -196.20 | -- | -- | -3,357.34 | -10,793.31 | -- | -129.66 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
| Enzo Biochem Inc | 33.34m | -17.55m | 57.12m | 179.00 | -- | 0.8237 | -- | 1.71 | -0.3516 | 0.9194 | 0.6633 | 1.35 | 0.4028 | 1.66 | 4.91 | 186,257.00 | -21.20 | -12.21 | -34.50 | -15.79 | 43.66 | 37.09 | -52.63 | -18.76 | 3.16 | -- | 0.053 | -- | -4.85 | -21.01 | -23.02 | -- | 7.89 | -- |
| Aileron Therapeutics Inc | 0.00 | -25.22m | 57.41m | 15.00 | -- | 1.02 | -- | -- | -3.25 | -3.25 | 0.00 | 4.67 | 0.00 | -- | -- | 0.00 | -40.88 | -65.99 | -43.02 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
Data as of Sep 19 2024. Currency figures normalised to Syros Pharmaceuticals Inc's reporting currency: US Dollar USD
46.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invus Public Equities Advisors LLCas of 25 Jul 2024 | 3.57m | 13.35% |
| Adage Capital Management LPas of 30 Jun 2024 | 2.07m | 7.75% |
| Avidity Partners Management LPas of 30 Jun 2024 | 1.67m | 6.26% |
| Point72 Asset Management LPas of 30 Jun 2024 | 1.47m | 5.51% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 964.24k | 3.61% |
| Opaleye Management, Inc.as of 30 Jun 2024 | 865.44k | 3.24% |
| Deep Track Capital LPas of 30 Jun 2024 | 828.49k | 3.10% |
| Kennedy Capital Management LLCas of 30 Jun 2024 | 427.54k | 1.60% |
| Walleye Capital LLCas of 30 Jun 2024 | 285.80k | 1.07% |
| UBS O'Connor LLCas of 30 Jun 2024 | 278.10k | 1.04% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
